Stephan Nopp1, Florian Moik1, Frederikus A Klok2, Dietlinde Gattinger3, Milos Petrovic3, Karin Vonbank4, Andreas R Koczulla5,6, Cihan Ay1, Ralf Harun Zwick3,7. 1. Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. 2. Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. 3. Outpatient Pulmonary Rehabilitation, Therme Wien Med, Vienna, Austria. 4. Clinical Division of Pulmonology, Department of Medicine II, Medical University of Vienna, Vienna, Austria. 5. Department of Pulmonary Rehabilitation, Member of the German Center for Lung Research (DZL), Philipps-University of Marburg, Marburg, Germany. 6. Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany. 7. Ludwig Boltzmann Institute Rehabilitation Research, Vienna, Austria.
Abstract
BACKGROUND: COVID-19 survivors face the risk of long-term sequelae including fatigue, breathlessness, and functional limitations. Pulmonary rehabilitation has been recommended, although formal studies quantifying the effect of rehabilitation in COVID-19 patients are lacking. METHODS: We conducted a prospective observational cohort study including consecutive patients admitted to an outpatient pulmonary rehabilitation center due to persistent symptoms after COVID-19. The primary endpoint was change in 6-min walk distance (6MWD) after undergoing a 6-week interdisciplinary individualized pulmonary rehabilitation program. Secondary endpoints included change in the post-COVID-19 functional status (PCFS) scale, Borg dyspnea scale, Fatigue Assessment Scale, and quality of life. Further, changes in pulmonary function tests were explored. RESULTS: Of 64 patients undergoing rehabilitation, 58 patients (mean age 47 years, 43% women, 38% severe/critical COVID-19) were included in the per-protocol-analysis. At baseline (i.e., in mean 4.4 months after infection onset), mean 6MWD was 584.1 m (±95.0), and functional impairment was graded in median at 2 (IQR, 2-3) on the PCFS. On average, patients improved their 6MWD by 62.9 m (±48.2, p < 0.001) and reported an improvement of 1 grade on the PCFS scale. Accordingly, we observed significant improvements across secondary endpoints including presence of dyspnea (p < 0.001), fatigue (p < 0.001), and quality of life (p < 0.001). Also, pulmonary function parameters (forced expiratory volume in 1 s, lung diffusion capacity, inspiratory muscle pressure) significantly increased during rehabilitation. CONCLUSION: In patients with long COVID, exercise capacity, functional status, dyspnea, fatigue, and quality of life improved after 6 weeks of personalized interdisciplinary pulmonary rehabilitation. Future studies are needed to establish the optimal protocol, duration, and long-term benefits as well as cost-effectiveness of rehabilitation.
BACKGROUND: COVID-19 survivors face the risk of long-term sequelae including fatigue, breathlessness, and functional limitations. Pulmonary rehabilitation has been recommended, although formal studies quantifying the effect of rehabilitation in COVID-19 patients are lacking. METHODS: We conducted a prospective observational cohort study including consecutive patients admitted to an outpatient pulmonary rehabilitation center due to persistent symptoms after COVID-19. The primary endpoint was change in 6-min walk distance (6MWD) after undergoing a 6-week interdisciplinary individualized pulmonary rehabilitation program. Secondary endpoints included change in the post-COVID-19 functional status (PCFS) scale, Borg dyspnea scale, Fatigue Assessment Scale, and quality of life. Further, changes in pulmonary function tests were explored. RESULTS: Of 64 patients undergoing rehabilitation, 58 patients (mean age 47 years, 43% women, 38% severe/critical COVID-19) were included in the per-protocol-analysis. At baseline (i.e., in mean 4.4 months after infection onset), mean 6MWD was 584.1 m (±95.0), and functional impairment was graded in median at 2 (IQR, 2-3) on the PCFS. On average, patients improved their 6MWD by 62.9 m (±48.2, p < 0.001) and reported an improvement of 1 grade on the PCFS scale. Accordingly, we observed significant improvements across secondary endpoints including presence of dyspnea (p < 0.001), fatigue (p < 0.001), and quality of life (p < 0.001). Also, pulmonary function parameters (forced expiratory volume in 1 s, lung diffusion capacity, inspiratory muscle pressure) significantly increased during rehabilitation. CONCLUSION: In patients with long COVID, exercise capacity, functional status, dyspnea, fatigue, and quality of life improved after 6 weeks of personalized interdisciplinary pulmonary rehabilitation. Future studies are needed to establish the optimal protocol, duration, and long-term benefits as well as cost-effectiveness of rehabilitation.
Authors: Roy Meys; Jeannet M Delbressine; Yvonne M J Goërtz; Anouk W Vaes; Felipe V C Machado; Maarten Van Herck; Chris Burtin; Rein Posthuma; Bart Spaetgens; Frits M E Franssen; Yvonne Spies; Herman Vijlbrief; Alex J Van't Hul; Daisy J A Janssen; Martijn A Spruit; Sarah Houben-Wilke Journal: J Clin Med Date: 2020-12-09 Impact factor: 4.241
Authors: Frederikus A Klok; Gudula J A M Boon; Stefano Barco; Matthias Endres; J J Miranda Geelhoed; Samuel Knauss; Spencer A Rezek; Martijn A Spruit; Jörg Vehreschild; Bob Siegerink Journal: Eur Respir J Date: 2020-07-02 Impact factor: 16.671
Authors: F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman Journal: Thromb Res Date: 2020-04-10 Impact factor: 3.944
Authors: Ewa Zasadzka; Sławomir Tobis; Tomasz Trzmiel; Renata Marchewka; Dominika Kozak; Anna Roksela; Anna Pieczyńska; Katarzyna Hojan Journal: Int J Environ Res Public Health Date: 2022-08-20 Impact factor: 4.614
Authors: Patricia Palau; Eloy Domínguez; Clara Sastre; M Luz Martínez; Cruz Gonzalez; Elvira Bondía; Crtstina Albiach; Julio Núñez; Laura López Journal: BMJ Open Respir Res Date: 2022-07
Authors: Ewan Donnachie; Alexander Hapfelmeier; Klaus Linde; Martin Tauscher; Roman Gerlach; Anna Greissel; Antonius Schneider Journal: BMJ Open Date: 2022-09-22 Impact factor: 3.006